Project Grant R42HL182546
Award Date 9/15/25
Completion Date 6/30/28
Dollars Obligated $312K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $349,734 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Actiox LLC, a biomedical technology company in Thousand Oaks, California. The project aims to develop a wearable microneedle-based biosensor for continuous, real-time cardiac troponin I monitoring. The goal is to demonstrate the feasibility of this transformative biosensor technology to enable earlier detection of ischemic events and...
- This federal Project Grant award of $110,635.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to characterize how red blood cell aggregation and membrane deformability affect endothelial cell injury and microvascular thrombosis in sepsis patients. The project will use microfluidics assays to analyze patient blood samples and apply machine learning to determine the impact of rheology on clinical outcomes. The research will also assess the...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Texas Tech University System provides $587,878 to develop novel additive-manufactured devices for label-free magnetophoresis to fractionate red blood cells (RBCs). The research aims to separate healthy, hemoglobin-enriched RBCs from damaged or iron-deficient cells to extend the shelf life of RBC units and enable transfusion therapies that can alleviate negative effects...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $432,431 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the San Jose State University Research Foundation. The grant, awarded on January 15, 2025, aims to study the deformability and subpopulation characteristics of red blood cells in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) compared to healthy controls. The research will...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...